EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Abaloparatide Maintains Normal Rat Blood Calcium Level in Part Via 1,25-Dihydroxyvitamin D/osteocalcin Signaling Pathway

Yanmei Yang, Wei-Ju Tseng, Bin Wang iD

Endocrinology · 2023

DOI: 10.1210/endocr/bqad117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, 2023. Verfasst von Yanmei Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Translational Medicine, Departments of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, U…. Hauptthemen laut MEDLINE: Parathyroid Hormone-Related Protein, Osteoporosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIAMS NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The PTH-related peptide(1-34) analog, abaloparatide (ABL), is the second anabolic drug available for the treatment of osteoporosis. Previous research demonstrated that ABL had a potent anabolic effect but caused hypercalcemia at a significantly lower rate. However, the mechanism by which ABL maintains the stability of blood calcium levels remains poorly understood. Our in vivo data showed that ABL treatment (40 µg/kg/day for 7 days) significantly increased rat blood level of 1,25-dihydroxyvitamin D [1,25-(OH)2D] without raising the blood calcium value. ABL also significantly augmented the carboxylated osteocalcin (Gla-Ocn) in the blood and bone that is synthesized by osteoblasts, and increased noncarboxylated Ocn, which is released from the bone matrix to the circulation because of osteoclast activation. The in vitro data showed that ABL (10 nM for 24 hours) had little direct effects on 1,25-(OH)2D synthesis and Gla-Ocn formation in nonrenal cells (rat osteoblast-like cells). However, ABL significantly promoted both 1,25-(OH)2D and Gla-Ocn formation when 25-hydroxyvitamin D, the substrate of 1α-hydroxylase, was added to the cells. Thus, the increased 1,25-(OH)2D levels in rats treated by ABL result in high levels of Gla-Ocn and transient calcium increase in the circulation. Gla-Ocn then mediates calcium ions in the extracellular fluid at bone sites to bind to hydroxyapatite at bone surfaces. This regulation by Gla-Ocn at least, in part, maintains the stability of blood calcium levels during ABL treatment. We conclude that the signaling pathway of ABL/1,25-(OH)2D/Gla-Ocn contributes to calcium homeostasis and may help understand the mechanism of ABL for osteoporosis therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parathyroid Hormone-Related ProteinOsteoporosisRatsAnimalsOsteocalcinCalciumSignal TransductionVitamin D

Stichwörter der Autor:innen

1,25-dihydroxyvitamin Dabaloparatideblood calciumbone biomarkercarboxylationosteocalcin

Substanzen

OsteocalcinParathyroid Hormone-Related ProteinCalcium1,25-dihydroxyvitamin DVitamin Dabaloparatide

Autor:innen und Institutionen

  • The Center for Translational Medicine, Departments of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Department of Orthopaedic Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.

ORCID-Profile: Bin Wang

Förderung

  • NIA NIH HHS
  • NIAMS NIH HHS
  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Yang, Y., Tseng, W. J., & Wang, B. (2023). Abaloparatide Maintains Normal Rat Blood Calcium Level in Part Via 1,25-Dihydroxyvitamin D/osteocalcin Signaling Pathway. Endocrinology. https://doi.org/10.1210/endocr/bqad117

Vancouver

Yang Y, Tseng WJ, Wang B. Abaloparatide Maintains Normal Rat Blood Calcium Level in Part Via 1,25-Dihydroxyvitamin D/osteocalcin Signaling Pathway. Endocrinology. 2023. doi:10.1210/endocr/bqad117

BibTeX
@article{Yang2023,
  author = {Yang, Yanmei and Tseng, Wei-Ju and Wang, Bin},
  title = {Abaloparatide Maintains Normal Rat Blood Calcium Level in Part Via 1,25-Dihydroxyvitamin D/osteocalcin Signaling Pathway},
  journal = {Endocrinology},
  year = {2023},
  doi = {10.1210/endocr/bqad117}
}
Kostenlos starten →